Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lupus Patients' shingles vaccine response under the microscope

NCT ID NCT07636044

First seen Jun 09, 2026 · Last updated Jun 22, 2026 · Updated 4 times

Summary

This study looks at how well the shingles vaccine (Shingrix) works in people with lupus compared to healthy people of the same age and sex. Researchers will measure immune cell responses after two doses and follow participants for up to 5 years. The goal is to understand if the vaccine provides adequate protection for those with lupus.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VACCINE REACTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Shingrix (adjuvanted herpes zoster subunit vaccine)

What this could lead to

If successful, this study could show that the Shingrix vaccine works well in people with lupus, helping protect them against shingles.

What could go wrong

This is an observational study, not a treatment trial. It only measures immune response, not actual shingles prevention. Results may not apply to all lupus patients.

Conditions

The condition(s) this trial relates to.

Herpes Zoster systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.